Calcium Gluconate Has No Established Role in Severe Dengue Management
Calcium gluconate is not indicated for the treatment of severe dengue and should not be routinely administered. The available evidence does not support its use in dengue management, and its administration could potentially cause harm without clinical benefit.
Why Calcium Gluconate Is Not Used in Dengue
The evidence provided relates exclusively to calcium gluconate's role in:
- Tumor lysis syndrome with symptomatic hypocalcemia 1
- Hypoparathyroidism with acute symptomatic hypocalcemia 2
- Hyperkalemia with cardiac manifestations 1, 3
- Calcium channel blocker toxicity 3, 4
None of these conditions are characteristic features of severe dengue.
What Actually Happens in Severe Dengue
Severe dengue is characterized by:
- Plasma leakage leading to hypovolemia and shock
- Hemorrhagic manifestations due to thrombocytopenia and coagulopathy
- Organ dysfunction (hepatic, neurological, cardiac)
While one recent observational study found hypocalcemia correlates with dengue severity 5, this represents an association, not a treatment target. The study showed 91.3% of severe dengue cases had hypocalcemia (<8.5 mg/dL), but provided no evidence that correcting calcium improves outcomes.
Evidence-Based Management of Severe Dengue
The cornerstone of severe dengue management is judicious fluid resuscitation 6. Current protocols emphasize:
- Early recognition of warning signs and plasma leakage
- Intravenous crystalloid fluids for patients with warning signs or shock
- Careful fluid balance to avoid both under-resuscitation (leading to shock) and over-resuscitation (causing pulmonary edema)
- Supportive care including blood product transfusion when indicated
The methodological review of dengue clinical practice guidelines globally 7 identified high-quality guidelines that consistently recommend fluid management as the primary intervention, with no mention of calcium supplementation.
Critical Pitfalls to Avoid
Do not administer calcium gluconate in severe dengue unless there is a specific, documented indication unrelated to dengue itself (e.g., concurrent hyperkalemia with ECG changes, documented symptomatic hypocalcemia from another cause).
Inappropriate calcium administration risks:
- Extravasation injury with tissue necrosis and calcinosis cutis 8
- Cardiac arrhythmias if administered too rapidly 9
- Hypercalcemia from overcorrection 10
- Diversion of resources from evidence-based interventions
When Calcium Might Be Considered (Rare Scenarios)
If a severe dengue patient develops documented symptomatic hypocalcemia (calcium ≤7 mg/dL or ionized calcium ≤0.8 mmol/L) with tetany, seizures, or prolonged QTc, then calcium gluconate would be indicated per standard hypocalcemia protocols 2:
- 1000 mg IV calcium gluconate (adults) over 10-30 minutes
- 100 mg/kg up to 1000 mg (children) over 30 minutes
- Cardiac monitoring during administration
- Measure serum calcium every 4-6 hours
However, this scenario would represent a concurrent condition requiring treatment, not a dengue-specific intervention.